ADMA Biologics Sued for Securities Law Violations
DJS Law Group notifies investors of a class action lawsuit against ADMA Biologics for alleged violations of securities laws. The suit claims the company provided misleading information regarding its business operations.
ADMA Biologics, Inc. is facing a class action lawsuit alleging violations of federal securities laws. The DJS Law Group, representing investors, announced the filing, which claims the company made materially false and misleading statements regarding its business. The lawsuit seeks to recover damages for investors who purchased ADMA Biologics stock.
The complaint specifically cites violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5 promulgated thereunder. These provisions are designed to prevent fraud and manipulation in the securities markets. Investors who acquired ADMA Biologics shares during the specified class period are urged to contact the DJS Law Group to learn more about their rights.
This legal action stems from allegations that ADMA Biologics provided investors with inaccurate information about its operations and financial health. The outcome of this lawsuit could have significant implications for the company's stock performance and reputation. The DJS Law Group is acting on behalf of investors who may have suffered financial losses due to the alleged misrepresentations.
Interested parties are advised to consult with the DJS Law Group to understand the details of the lawsuit and determine their eligibility to participate. The firm is investigating the extent of the alleged violations and the potential for recovery for affected shareholders.